RCS - Eden Research plc - Appointment of new Head of Regulatory Affairs

Eden ResearchAnnouncement

15/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240815:nRSO4804Aa&default-theme=true

RNS Number : 4804A  Eden Research plc  15 August 2024

15 August 2024

 

 

Eden Research Plc

("Eden" or "Company")

 

Appointment of new Head of Regulatory Affairs

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and
biocontrol technology, is pleased to announce the appointment of Ilshad Moulan
as the Company's new Head of Regulatory Affairs. Ilshad will bring his
experience in the agrochemical sector to lead Eden Research's regulatory
strategy and execution, helping to ensure the successful global registration
of its innovative crop protection solutions.

 

Ilshad has strong expertise in regulatory affairs management having led teams
and managed complex projects across the industry. With a BSc degree in
Biochemistry and Cell Biology and an MSc degree in Crop Protection and
Regulatory Science, his strong scientific background complements his
regulatory expertise.

 

At Dr. Knoell Consult Ltd, Ilshad led a team of nine, focusing on regulatory
affairs. His career began at Agrauxine, where he played a key role in
developing dossiers for biopesticide active ingredients and formulated plant
protection products. Additionally, his previous roles at Evergreen Garden Care
and Battelle involved supporting and managing regulatory submissions for
conventional active ingredients and formulated products.

 

Ilshad Moulan commented:

 

"I am thrilled to join Eden Research at such an exciting time. I look forward
to using my regulatory expertise to support Eden's mission of delivering
sustainable solutions to the agricultural sector and ensuring our products
reach farmers worldwide as quickly and efficiently as possible."

 

Ilshad will be based at Eden Research's headquarters in Oxfordshire and will
begin his new role immediately. He succeeds Dr. Mike Carroll who will retire
at the end of a handover period. Mike has served as Eden's first-ever
regulatory leader and played a key role in not only establishing Eden's
in-house regulatory capabilities, but in successfully expanding the regulatory
authorisations for Eden's existing and new products.

 

Sean Smith, CEO of Eden Research, added:

 

"We are delighted to welcome Ilshad to our team. His extensive background in
regulatory affairs, combined with his leadership skills, will be a tremendous
asset as we continue to navigate the complex regulatory landscape and bring
our sustainable biopesticide products to market.  At the same time, we thank
Mike for all of his contributions over the past four years.  His experience
and leadership have been helpful in propelling our business forward and
expanding our geographical footprint, and we are grateful for all his
contributions. We wish Mike all the best for a long, happy retirement."

 

 

For further information contact:

 

 Eden Research plc
 Sean Smith                                                        www.edenresearch.com (http://www.edenresearch.com)

Alex Abrey

                                                                 01285 359 555

 Cavendish Capital Markets Limited (Nominated advisor and broker)
 Giles Balleny / George Lawson (corporate finance)                 020 7220 0500

Charlie Combe (corporate broking)

Michael Johnson (sales)

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                                eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar
biofungicide which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops.  It is a useful tool in crop defence
programmes and is aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries whilst Eden
and its partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.

 

Cedroz™( )is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's seed treatment product, Ecovelex was developed to safely tackle crop
destruction caused by birds - a major cause of losses in maize and other
crops. Ecovelex works by creating an unpleasant taste or odour that repels
birds, leaving the seeds safely intact and the birds unaffected and free to
find alternative food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, U.S. and elsewhere, and formulated using
Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine(®)( )encapsulation technology is used to harness the
biocidal efficacy of naturally occurring chemicals produced by plants
(terpenes) and can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres derived from
yeast. It is one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the
symbol EDEN. It was awarded the London Stock Exchange Green Economy
Mark in January 2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services that
contribute to the global green economy. Eden derives 100% of its total annual
revenues from sustainable products and services.

For more information about Eden, please visit:  www.edenresearch.com
(http://www.edenresearch.com/) .

 

 

ENDS

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKQBPNBKDOFD